Evidence map›Paper›PMID 38554191›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Potential of semen coicis in enhancing the anti-tumor effects of PD-1 inhibitor on A549 cell lines by blocking the PI3K-AKT-mTOR pathway.

Zi-Yi Fu, Ying Huang, Le-Shen Lian, Hui-Ting Huang, Shao-Feng Zhan, Yan Cai, Jun-Xiong Li, Xiao-Hong Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zi-Yi FuThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
Ying HuangDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
Le-Shen LianDepartment of Pulmonary and Critical Care Medicine, Dongguan Hospital Affiliated to Guangzhou University of Chinese Medicine, Dongguan, 523000, China.
Hui-Ting HuangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
Shao-Feng ZhanDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
Yan CaiDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
Jun-Xiong LiDepartment of Pulmonary and Critical Care Medicine, Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Foshan, 528000, China.
Xiao-Hong LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000, China. rsclxhgzcum@163.com.ORCID http://orcid.org/0009-0004-0979-5396
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of this research was to investigate how the combination of semen coicis extract and PD-1 inhibitors can potentially work together to enhance the anti-tumor effects, with a focus on understanding the underlying mechanism.

methodsWe obtained the active components and specific targets of semen coicis in the treatment of NSCLC from various databases, namely TCMSP, GeneCard, and OMIM. By utilizing the STRING database and Cytoscape software, we established a protein interaction network (PPI) for the active ingredient of semen coicis and the target genes related to NSCLC. To explore the potential pathways involved, we conducted gene ontology (GO) and biological pathway (KEGG) enrichment analyses, which were further supported by molecular docking technology. Additionally, we conducted cyto-inhibition experiments to verify the inhibitory effects of semen coicis alone or in combination with a PD-1 inhibitor on A549 cells, along with examining the associated pathways. Furthermore, we investigated the synergistic mechanism of these two drugs through cytokine release experiments and the PD-L1 expression study on A549 cells.

resultsSemen coicis contains two main active components, Omaine and (S)-4-Nonanolide. Its primary targets include PIK3R1, PIK3CD, PIK3CA, AKT2, and mTOR. Molecular docking experiments confirmed that these ingredients and targets form stable bonds. In vitro experiments showed that semen coicis demonstrates inhibitory effects against A549 cells, and this effect was further enhanced when combined with PD-1 inhibitors. PCR and WB analysis confirmed that the inhibition of the PI3K-AKT-mTOR pathway may contribute to this effect. Additionally, semen coicis was observed to decrease the levels of IFN-γ, IL-6, and TNF-α, promoting the recovery of the human anti-tumor immune response. And semen coicis could inhibit the induced expression of PD‑L1 of A549 cells stimulated by IFN‑γ as well.

conclusionSemen coicis not only has the ability to kill tumor cells directly but also alleviates the immunosuppression found in the tumor microenvironment. Additionally, it collaboratively enhances the effectiveness of PD-1 inhibitors against tumors by blocking the activation of PI3K-AKT-mTOR.

Indexed as

Antineoplastic AgentsCoixLung NeoplasmsProgrammed Cell Death 1 ReceptorSignal TransductionA549 CellsB7-H1 AntigenCarcinoma, Non-Small-Cell LungDrug SynergismHumansImmune Checkpoint InhibitorsMolecular Docking SimulationPhosphatidylinositol 3-KinasesProtein Interaction MapsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesAntineoplastic AgentsB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsMTOR protein, humanPDCD1 protein, humanPhosphatidylinositol 3-KinasesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesA549 cellNetwork pharmacologyPD-1 inhibitorPI3K-AKT-mTOR signal pathwaySemen coicis

Identifiers

PMID38554191
OpenAlexW4393333820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.